Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNT1 | O60563 | 14/20 | 0.44 |
| ▸ | CDK9 | P50750 | 14/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9108829 | 0.95 | EPHX2 (0.40) | CCNT1CDK9MEN1KMT2AEPHX2 | |
| SCHEMBL9103135 | 0.94 | CCNT1 (0.49) | CCNT1CDK9MEN1KMT2A | |
| SCHEMBL9103928 | 0.93 | CCNT1 (0.45) | CCNT1CDK9 | |
| SCHEMBL9107573 | 0.92 | EPHX2 (0.39) | CCNT1CDK9EPHX2HSD17B10 | |
| SCHEMBL9103993 | 0.92 | CCNT1 (0.42) | CCNT1CDK9MEN1KMT2AHSD17B10 | |
| SCHEMBL9104266 | 0.92 | CDK9 (0.47) | CCNT1CDK9MEN1KMT2ABRD4 | |
| SCHEMBL1437591 | 0.90 | EPHX2 (0.42) | CCNT1CDK9KMT2AEPHX2HSD17B10 | |
| SCHEMBL1437819 | 0.90 | CCNT1 (0.40) | CCNT1CDK9MEN1KMT2AHSD17B10 | |
| SCHEMBL1442627 | 0.90 | CCNT1 (0.40) | CCNT1CDK9MEN1KMT2AHSD17B10 | |
| SCHEMBL9897963 | 0.90 | MEN1 (0.40) | CCNT1CDK9MEN1KMT2AEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8816085-B2 | Methylpyrrolopyridinecarboxamides | TAKEDA GMBH (DE) | 2014-08-26 | — | — | US | claimed |
| US-8816085-B2 | Methylpyrrolopyridinecarboxamides | TAKEDA GMBH (DE) | 2014-08-26 | — | — | US | disclosed |
| US-20120142633-A1 | METHYLPYRROLOPYRIDINECARBOXAMIDES | NYCOMED GMBH (DE) | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142633-A1 | METHYLPYRROLOPYRIDINECARBOXAMIDES | PDE5A, PDE3A, PDE2A | CCNT1 1888/4885CDK9 1048/4885MEN1 2045/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.